The research published in the British Journal of Haematology found that early progression after quadruplet combinations for multiple myeloma (MM) predicts subsequent early progression on later treatment lines. Among patients with newly diagnosed MM, quadruplet combinations are a main treatment. There are no standardized guidelines for progressing transplant-eligible patients after quadruplet therapy. The study evaluated outcomes of newly diagnosed patients with MM treated with a quadruplet combination eligible for transplantation, and found that the response rate to next therapy was 26.3% among patients who progressed before 18 months. Overall, the study indicated the need to refine predictors of treatment failure. Some study authors have affiliations with biotech, pharmaceutical, or device companies.
Source link
Early Quadruplet Treatment Failure for MM Predicts Earlier Progression in Later Lines
